HSDD

The positive late-stage results for female arousal drug from Palatin Technologies, Inc. (NYSE: PTN) once again throw light on the underappreciated market of female sexual health. Palatin announced the late-stage study of bremelanotide met its primary endpoint to treat hypoactive sexual desire...